Skip to content

Development and Validation of a Comprehensive Classification Automation System for Kidney Allograft Biopsies

Development, Application, and Validation of a Comprehensive Classification Automation System for Allograft Precision Diagnostics in Adult and Pediatric Kidney Transplant Biopsies

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05306795
Enrollment
4000
Registered
2022-04-01
Start date
2016-01-01
Completion date
2022-12-01
Last updated
2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant Rejection, Pathology

Keywords

Banff classification, Kidney transplantation, Precision diagnostic, Automation

Brief summary

Since 1991, the Banff classification has been the gold standard for defining antibody-mediated rejection (AMR) and T-cell mediated rejection (TCMR), thereby guiding the treatment and management of transplant recipients. Starting from a pure histological approach, the classification has moved over the past three decades towards an integrated precision diagnosis system, which encompasses other expertise, such as immunology, immunogenetic, other basic sciences, biostatistics, data science, and artificial intelligence The counterpart of this constant refinement is that Banff rules are becoming complex to follow, with numerous possible scenarios leading to a high degree of inter-observer variability and misclassifications, which may lead to therapeutic consequences. The aims of this study are: 1. To integrate and decode all Banff rules and develop a computer-based application - the Banff Automation System - which provides automated and reproducible diagnoses 2. To validate the ability of the Banff Automation System to reclassify rejection diagnoses in multicenter cohort studies and clinical trials.

Detailed description

Despite considerable advances in the development of effective immunosuppressive therapies, allograft rejection remains the main cause of graft loss after kidney transplantation. Since 1991, the Banff classification has been the gold standard for defining antibody-mediated rejection (AMR) and T-cell mediated rejection (TCMR), thereby guiding the treatment and management of transplant recipients. Starting from a pure histological approach, the classification has moved over the past three decades towards an integrated precision diagnosis system, which encompasses other expertise, such as immunology, immunogenetic, other basic sciences, biostatistics, data science, and artificial intelligence The counterpart of this constant refinement is that Banff rules are becoming complex to follow, with numerous possible scenarios leading to a high degree of inter-observer variability and misclassifications, which may lead to therapeutic consequences. Hence, international transplant societies and regulatory agencies urgently appealed for a more comprehensible and reproducible classification, required for decision-making process and reliable surrogate endpoints, to further improve patients care and drug development. The aims of this study are: 1. To integrate and decode all Banff rules and develop a computer-based application - the Banff Automation System - which provides automated and reproducible diagnoses 2. To validate the ability of the Banff Automation System to reclassify rejection diagnoses in multicenter cohort studies and clinical trials. Based on the results, the investigators will provide a comprehensive, user-friendly, and open-access online application which might improve reproducibility and precision of biopsies' diagnoses, thereby reducing misclassifications, and path the way to standardize histology-based endpoints in observational studies and clinical trials, and post-transplant diagnostic and therapeutic's management of kidney transplant recipients.

Interventions

None listed

Sponsors

Paris Translational Research Center for Organ Transplantation
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Kidney transplant recipients * At least one kidney transplant biopsy performed, assessed with the Banff classification

Exclusion criteria

* Inadequate biopsy according to the Banff classification (number of glomeruli inferior less than seven) * Missing data for Banff lesion scores * Missing data for donor-specific antibody status * Missing data for C4d (degradation product of the classic complement pathway) staining

Design outcomes

Primary

MeasureTime frameDescription
Rejection-related diagnoses reclassified by the computer-based tool1 day (At time of a kidney allograft biopsy)Proportion of rejection-related diagnoses reclassified by the computer-based tool

Secondary

MeasureTime frameDescription
Graft survival24 months post-kidney allograft biopsyComparison of graft survival after diagnosis by the computer-based tool

Countries

France

Contacts

Primary ContactAlexandre Loupy, MD, PhD
alexandre.loupy@inserm.fr(33)153988000
Backup ContactCatherine Tritscher
tritschercatherine@gmail.com(33)153988000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026